The Trial Lawyer Magazine Logo

Safyral Expected to Emerge from the Litigation Shadows; October 21, 2013

Washington, DC: As evidenced by the contents of the second-quarter performance summary issued by pharmaceutical giant Bayer, the German manufacturer had settled about 6,760 claims with regard to drospirenone side effects, costing the company about $1.4 billion as of July 8 of this year. Another 5,400 US lawsuits are still pending.

However, of those settlements, it appears as if Safyral has taken a back seat to the more well-known drospirenone contraceptives under the brand names Yasmin, Yaz, Ocella and some Gianvi cases. According to the blog Drug Industry Watch (9/4/13), industry watchers expect that lawsuits alleging Safyral blood clots, together with cases alleging side effects from Beyaz, will be next in line.

There is little doubt that Yasmin and Yaz have been getting most of the press, and is top of mind with consumers who have acquired an awareness of the products and issues surrounding drospirenone side effects, even if they don’t actually use the products.

To read the complete article, please click here:

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram